(Q82353617)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054920%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Traditional approaches to androgen deprivation therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054920%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

4

0 references

author name string

Judd W Moul

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054920%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Christopher P Evans

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054920%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Leonard G Gomella

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054920%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Robert Dreicer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054920%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

English

0 references

publication date

1 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054920%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054920%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

78

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054920%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

S485-93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054920%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

5 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054920%20AND%20SRC:MED&resulttype=core&format=json

STUDIES ON PROSTATIC CANCER

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Screening, risk assessment, and the approach to therapy in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Lack of prostate cancer radiosensitization by androgen deprivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

To treat pelvic nodes or not? Greater testicular scatter does not explain the results of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Duration of androgen suppression in the treatment of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

EAU guidelines on prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Combination hormonal therapy: a reassessment within advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.05.051

10.1016/J.UROLOGY.2011.05.051

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22054920%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference